December 01, 2015.
Novartis is paying $390 million to settle charges that it paid kickbacks to pharmacies to encourage drug sales, reports Specialty Pharmacy Times.
A US government lawsuit maintained that a US unit of Novartis violated the False Claims Act and the Anti-Kickback Statute with its incentives to sell the iron chelator Exjade and the immunosuppressant Myfortic.
Novartis allegedly gave patient referrals, discounts, and rebates to Accredo Health Group, Bioscrip Inc, and US Bioservices Corporation to encourage these specialty pharmacies to recommend that patients order Exjade refills.
The lawsuit also alleged that Novartis paid kickbacks in the form of rebates to the pharmacies so that they would encourage refills of the oral iron chelator.
For more on this story, click here.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.